申请人:Nagayama Satoshi
公开号:US20090318497A1
公开(公告)日:2009-12-24
This invention provides a compound of the formula (I): wherein A
1
is N and A
2
is CR
7
, or A
1
is CR
7
and A
2
is N; Y
1
, Y
2
and Y
3
are each independently CH or N, Y
4
and Y
5
are each independently CR
8
or N, with the proviso that when one of Y
1
, Y
2
, Y
3
, Y
4
and Y
5
is N, the others are not N; R
1
and R
2
are each independently hydrogen, halogen, (C
1
-C
6
)alkyl, halo(C
1
-C
6
)alkyl or hydroxy(C
1
-C
6
)alkyl; R
3
and R
8
are each independently hydrogen, halogen, hydroxy, (C
1
-C
6
)alkyl, hydroxy(C
1
-C
6
)alkoxy, (C
1
-C
6
)alkoxy-(C
1
-C
6
)alkyl, (C
1
-C
6
)alkoxy-(C
1
-C
6
)alkoxy, halo(C
1
-C
6
)alkyl, (C
1
-C
6
)alkylthio, (C
1
-C
6
)alkylsulfinyl or (C
1
-C
6
)alkylsulfonyl; R
4
is halogen, (C
1
-C
6
)alkyl, (C
3
-C
6
)cycloalkyl, halo(C
1
-C
6
)alkyl, hydroxy(C
1
-C
6
)alkyl, halo(C
1
-C
6
)alkoxy, hydroxy(C
1
-C
6
)alkoxy, (C
1
-C
6
)alkoxy-(C
1
-C
6
)alkyl, (C
1
-C
6
)alkoxy-(C
1
-C
6
)alkoxy, halo(C
1
-C
6
)alkylsulfonyl, halo(C
1
-C
6
)alkylsulfinyl, halo(C
1
-C
6
)alkylthio, [(C
1
-C
6
)alkyl]NH— or [(C
1
-C
6
)alkyl]
2
N—; and R
5
, R
6
and R
7
are each independently hydrogen, halogen, (C
1
-C
6
)alkyl, hydroxy(C
1
-C
6
)alkyl, or (C
1
-C
6
)alkoxy; or a pharmaceutically acceptable salt, solvate thereof. These compounds are useful for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical composition comprising the above compound.
本发明提供了一种式(I)的化合物:其中A1为N且A2为CR7,或者A1为CR7且A2为N;Y1、Y2和Y3分别独立地为CH或N,Y4和Y5分别独立地为CR8或N,但是当Y1、Y2、Y3、Y4和Y5中的一个为N时,其他的不为N;R1和R2各自独立地为氢、卤素、(C1-C6)烷基、卤代(C1-C6)烷基或羟基(C1-C6)烷基;R3和R8各自独立地为氢、卤素、羟基、(C1-C6)烷基、羟基(C1-C6)氧烷基、(C1-C6)氧烷基-(C1-C6)烷基、(C1-C6)氧烷基-(C1-C6)氧烷基、卤代(C1-C6)烷基、(C1-C6)烷基硫醇基、(C1-C6)烷基亚砜基或(C1-C6)烷基磺酰基;R4为卤素、(C1-C6)烷基、(C3-C6)环烷基、卤代(C1-C6)烷基、羟基(C1-C6)烷基、卤代(C1-C6)氧烷基、羟基(C1-C6)氧烷基、(C1-C6)氧烷基-(C1-C6)烷基、(C1-C6)氧烷基-(C1-C6)氧烷基、卤代(C1-C6)烷基磺酰基、卤代(C1-C6)烷基亚砜基、卤代(C1-C6)烷基硫醇基、[(C1-C6)烷基]NH-或[(C1-C6)烷基]2N-;以及R5、R6和R7各自独立地为氢、卤素、(C1-C6)烷基、羟基(C1-C6)烷基或(C1-C6)氧烷基;或其药学上可接受的盐、溶剂。这些化合物对于治疗由VR1受体过度激活引起的疾病状况,例如哺乳动物中的疼痛等,是有用的。本发明还提供了包含上述化合物的制药组合物。